

## Supporting information (SI)

# Safe and sustainable by design: Case study of a magnetic torus microreactor and bionanocompounds for wastewater treatment

*Olga P. Fuentes*<sup>a</sup>, *Amaimen Guillén-Pacheco*<sup>b,c</sup>, *Johann F. Osma*<sup>d,e</sup>, *Guido Sonnemann*<sup>a\*</sup>

<sup>a</sup> Univ. Bordeaux, CNRS, Bordeaux INP, ISM, UMR 5255, F-33400, Talence, France.

<sup>b</sup> Davinci - School of Basic Sciences, Technology, and Engineering (ECBIT), Electronic, Telecommunication, and Network Training Chain (ETR), Universidad Nacional Abierta y a Distancia (UNAD), Calle 14 Sur No. 14–23, 111711, Bogotá, DC, Colombia.

<sup>c</sup> Laboratory of Neuroscience and Circadian Rhythms. School of Medicine, Universidad de Los Andes, Cra. 1E No. 19a-40, 111711, Bogotá, DC, Colombia.

<sup>d</sup> Department of Electrical and Electronic Engineering, Universidad de Los Andes, Cra. 1E No. 19a-40, 111711, Bogotá, DC, Colombia.

<sup>e</sup> Department of Biomedical Engineering, Universidad de Los Andes, Cra. 1E No. 19a-40, 111711, Bogotá, DC, Colombia.


**\*Corresponding author**

Guido Sonnemann; E-mail: [guido.sonnemann@u-bordeaux.fr](mailto:guido.sonnemann@u-bordeaux.fr)

Number of pages: 30

Number of tables: 27

Number of figures: 4



**Figure S-1.** Schematic representation of the wastewater treatment process. The magnetic torus microreactor has a continuous operation, allowing a steady flow of wastewater through the inlet, along the microchannels, and toward the outlet. As the wastewater (dye solution) moves through the microchannels, it encounters the MNPs@laccase solution, which is held in place by the magnetic field of a permanent magnet. During this interaction, the wastewater is treated by the immobilized MNPs@laccase. While the treated wastewater continues its flow toward the outlet, the MNPs@laccase remains retained within the microreactor. Adapted from Peñaranda et al. study.<sup>1</sup>

**Table S-1.** Measured water quality parameters of the real wastewater used in this study. Adapted from Peñaranda et al. study.<sup>1</sup>

| Wastewater Compound             | Value  | Units                |
|---------------------------------|--------|----------------------|
| Phenols                         | 19.60  | mg Phenol/l          |
| Biochemical oxygen demand (BOD) | 385.00 | mg O <sub>2</sub> /l |
| NH <sub>3</sub> nitrogen        | 0.60   | mg N/l               |
| Kjeldahl nitrogen               | 12.40  | mg N/l               |

**Table S-2.** Raw material information from ECHA database (Step 1).

| Name                         | Acronym   | CAS number | Source  |
|------------------------------|-----------|------------|---|
| Methyl methacrylate*         | PMMA      | 80-62-6    | <a href="https://echa.europa.eu/es/registration-dossier/-/registered-dossier/15528">https://echa.europa.eu/es/registration-dossier/-/registered-dossier/15528</a> |
| Bis(4-fluorophenyl) ketone** | PEEK      | 345-92-6   | <a href="https://echa.europa.eu/es/registration-dossier/-/registered-dossier/5154">https://echa.europa.eu/es/registration-dossier/-/registered-dossier/5154</a>   |
| Copper***                    | Rivets    | 7440-50-8  | <a href="https://echa.europa.eu/es/registration-dossier/-/registered-dossier/15562">https://echa.europa.eu/es/registration-dossier/-/registered-dossier/15562</a> |
| Ethanol                      | -         | 64-17-5    | <a href="https://echa.europa.eu/es/registration-dossier/-/registered-dossier/16105">https://echa.europa.eu/es/registration-dossier/-/registered-dossier/16105</a> |
| Iron dichloride****          | Iron (II) | 7758-94-3  | <a href="https://echa.europa.eu/es/registration-dossier/-/registered-dossier/15494">https://echa.europa.eu/es/registration-dossier/-/registered-dossier/15494</a> |

|                               |            |           |   |
|-------------------------------|------------|-----------|---|
| Iron trichloride*****         | Iron (III) | 7705-08-0 | <a href="https://echa.europa.eu/es/registration-dossier/-/registered-dossier/16109">https://echa.europa.eu/es/registration-dossier/-/registered-dossier/16109</a> |
| Sodium hydroxide              | NaOH       | 1310-73-2 | <a href="https://echa.europa.eu/es/registration-dossier/-/registered-dossier/15566">https://echa.europa.eu/es/registration-dossier/-/registered-dossier/15566</a> |
| Tetramethylammonium hydroxide | TMAH       | 75-59-2   | <a href="https://echa.europa.eu/es/registration-dossier/-/registered-dossier/14295">https://echa.europa.eu/es/registration-dossier/-/registered-dossier/14295</a> |

\* Chemical substance assumed for polymethyl methacrylate (PMMA) production.

\*\* Chemical substance assumed for PEEK fittings production as thermoplastics.

\*\*\* Chemical substance assumed for rivets fittings production.

\*\*\*\* Chemical substance assumed for Iron (II) chloride tetrahydrate.

\*\*\*\*\* Chemical substance assumed for Iron (III) chloride hexahydrate.

**Table S-3.** Classification of the raw materials used in the wastewater treatment based on the ECHA database information – Human Health (HH) hazards (Step 1).

| Human health hazards                                | Raw materials       |        |         |      |                 |          |           |      |
|---|---------------------|--------|---------|------|-----------------|----------|-----------|------|
|   | Manufacturing stage |        |         |      | Operation stage |          |           |      |
|   | PMMA                | Rivets | Ethanol | PEEK | NaOH            | Iron(II) | Iron(III) | TMAH |
| Acute toxicity - oral                               | NC                  | NC     | NC      | 4    | NC              | 4        | 4         | 2    |
| Acute toxicity - dermal                             | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | 1    |
| Acute toxicity - inhalation                         | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | DL   |
| Skin corrosion/irritation                           | 2                   | NC     | NC      | NC   | 1A              | NC       | 2         | 1B   |
| Serious eye damage/eye irritation                   | NC                  | NC     | 2       | NC   | 1               | 1        | 1         | 1    |
| Respiratory sensitisation                           | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | DL   |
| Skin sensitisation                                  | 1                   | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Aspiration hazard                                   | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | DL   |
| Reproductive toxicity                               | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Effects on or via lactation                         | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | DL   |
| Germ cell mutagenicity                              | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Carcinogenicity                                     | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | DL   |
| Specific target organ toxicity - single (STOT-SE)   | 3                   | NC     | NC      | DL   | NC              | NC       | NC        | 1    |
| Specific target organ toxicity - repeated (STOT-RE) | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | 1    |

|      |  |
|------|--|
| NC   | Not classified according to CLP criteria               |
| Cat. | Classified according to CLP criteria - Hazard category |
| DL   | Data lacking   |

**Table S-4.** Classification of the raw materials used in the wastewater treatment based on the ECHA database information – Environmental hazard (Step 1).

| Environmental hazard         | Raw materials       |        |         |        |                 |          |           |        |
|------------------------------|---------------------|--------|---------|--------|-----------------|----------|-----------|--------|
|                              | Manufacturing stage |        |         |        | Operation stage |          |           |        |
|                              | PMMA                | Rivets | Ethanol | PEEK   | NaOH            | Iron(II) | Iron(III) | TMAH   |
| PBT/vPvB                     | No PBT              | N/A    | No PBT  | No PBT | N/A             | N/A      | N/A       | No PBT |
| PMT/vPvM                     | DL                  | DL     | DL      | DL     | DL              | DL       | DL        | DL     |
| Aquatic toxicity (acute)     | NC                  | NC     | NC      | DL     | NC              | NC       | NC        | NC     |
| Aquatic toxicity (long-term) | NC                  | NC     | NC      | 2      | NC              | NC       | NC        | 2      |
| Ozone layer                  | NC                  | NC     | NC      | DL     | NC              | NC       | NC        | DL     |

|        |  |
|--------|--|
| NC     | Not classified according to CLP criteria               |
| Cat.   | Classified according to CLP criteria - Hazard category |
| DL     | Data lacking   |
| No PBT | The substance is not PBT/vPvB                          |
| N/A    | PBT assessment does not apply                          |

**Table S-5.** Classification of the raw materials used in the wastewater treatment based on the ECHA database information – Physical hazard (Step 1).

| Physical hazards                              | Raw materials       |        |         |      |                 |          |           |      |
|---|---------------------|--------|---------|------|-----------------|----------|-----------|------|
|   | Manufacturing stage |        |         |      | Operation stage |          |           |      |
|   | PMMA                | Rivets | Ethanol | PEEK | NaOH            | Iron(II) | Iron(III) | TMAH |
| Explosives                                    | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Flammable gases and chemically unstable gases | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Aerosols                                      | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Oxidising gases                               | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Gases under pressure                          | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Flammable liquids                             | 2                   | NC     | 2       | DL   | NC              | NC       | NC        | NC   |
| Flammable solids                              | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Self-reactive substances                      | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Pyrophoric solids                             | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Self-heating substances                       | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Emits flammable gases                         | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Oxidising liquids                             | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Oxidising solids                              | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Organic peroxides                             | NC                  | NC     | NC      | DL   | NC              | NC       | NC        | NC   |
| Corrosive to metals                           | NC                  | NC     | DL      | DL   | 1               | 1        | 1         | DL   |
| Desensitized explosives                       | NC                  | NC     | DL      | DL   | DL              | DL       | DL        | NC   |

|      |  |
|------|--|
| NC   | Not classified according to CLP criteria               |
| Cat. | Classified according to CLP criteria - Hazard category |
| DL   | Data lacking   |

**Table S-6.** Data lacking justification: For some materials, the hazard profile could not be fully calculated due to missing information in certain hazard categories. The justifications provided address these data gaps, enabling the completion of the hazard profiles for use in the SSbD evaluation process.

|   |   | PMMA   | Rivets | Ethanol               | PEEK   | NaOH | Iron(II) | Iron(III) | TMAH   |
|---|---|--|--------|-----------------------|--|------|----------|-----------|--|
| <b>Human health hazards</b>                         | Acute toxicity - inhalation                       | -  | -      | -                     | Its high molecular weight and solid form limit the likelihood of inhalable exposure under normal use, and testing is rarely conducted                      | -    | -        | -         | Inhalation studies are scarce, with most toxicological data focusing on dermal and oral exposure routes due to its typical liquid handling |
|   | Respiratory sensitisation                         | -  | -      | -                     | No experimental or epidemiological data available  | -    | -        | -         | No experimental or epidemiological data available  |
|   | Aspiration hazard                                 | -  | -      | -                     | Hazard class not applicable since it is a solid polymer  | -    | -        | -         | Hazard class not applicable testing is not typically performed   |
|   | Reproductive toxicity                             | -  | -      | -                     | No conclusive studies  | -    | -        | -         | -  |
|   | Effects on or via lactation                       | -  | -      | -                     | This category requires evidence of substance transfer into breast milk and subsequent toxicity to infants. No such studies are available for this material | -    | -        | -         | No available studies   |
|   | Carcinogenicity                                   | -  | -      | -                     | No long-term carcinogenicity studies were found  | -    | -        | -         | This substance lacks chronic exposure datasets, likely due to handling controls in industrial settings                                     |
|   | Specific target organ toxicity - single (STOT-SE) | -  | -      | -                     | No data are available. No acute organ effects are expected from brief exposure   | -    | -        | -         | -  |
| Specific target organ toxicity - repeated (STOT-RE) | -   | -  | -      | No data are available | -  | -    | -        | -         |  |
| <b>Environmental hazard</b>                         | PMT/vPvM  | These endpoints are relatively new under chemical regulations, and testing is not yet widespread |        |                       |  |      |          |           |  |
|   | Aquatic toxicity (acute)                          | -  | -      | -                     | No acute aquatic toxicity data found   | -    | -        | -         | -  |
|   | Ozone layer                                       | -  | -      | -                     | No data available. Testing is generally focused on halogenated compounds with ozone-depleting potential. PEEK doesn't exhibit such structural features     | -    | -        | -         | There is no known environmental pathway by which TMAH could impact the stratospheric ozone layer   |
| <b>Physical hazards</b>                             | Flammable gases and chemically unstable gases     | -  | -      | -                     | PEEK is generally regarded as thermally stable and chemically inert, so these tests are not commonly performed outside of specific regulatory framework    | -    | -        | -         | -  |
|   | Aerosols  | -  | -      | -                     |  | -    | -        | -         | -  |
|   | Oxidising gases                                   | -  | -      | -                     |  | -    | -        | -         | -  |
|   | Gases under pressure                              | -  | -      | -                     |  | -    | -        | -         | -  |
|   | Flammable liquids                                 | -  | -      | -                     |  | -    | -        | -         | -  |

|  |                          |   |   |   |  |   |   |   |                       |
|--|--------------------------|---|---|---|--|---|---|---|-----------------------|
|  | Self-reactive substances | - | - | -   |  | - | - | - | -                     |
|  | Pyrophoric solids        | - | - | -   |  | - | - | - | -                     |
|  | Self-heating substances  | - | - | -   |  | - | - | - | -                     |
|  | Emits flammable gases    | - | - | -   |  | - | - | - | -                     |
|  | Oxidising liquids        | - | - | -   |  | - | - | - | -                     |
|  | Organic peroxides        | - | - | -   |  | - | - | - | -                     |
|  | Corrosive to metals      | - | - | No data are available   |  | - | - | - | No data are available |
|  | Desensitized explosives  | - | - | These substances are not explosives in their pure form, and thus classification is not relevant |  |   |   | - |                       |

**Table S-7.** Final classification of Human Health (HH) hazards (Step 1).

| Human health hazards                                | Raw materials       |        |         |      |                 |          |           |      |
|---|---------------------|--------|---------|------|-----------------|----------|-----------|------|
|   | Manufacturing stage |        |         |      | Operation stage |          |           |      |
|   | PMMA                | Rivets | Ethanol | PEEK | NaOH            | Iron(II) | Iron(III) | TMAH |
| Acute toxicity - oral                               | NC                  | NC     | NC      | 4    | NC              | 4        | 4         | 2    |
| Acute toxicity - dermal                             | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | 1    |
| Acute toxicity - inhalation                         | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Skin corrosion/irritation                           | 2                   | NC     | NC      | NC   | 1A              | NC       | 2         | 1B   |
| Serious eye damage/eye irritation                   | NC                  | NC     | 2       | NC   | 1               | 1        | 1         | 1    |
| Respiratory sensitisation                           | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Skin sensitisation                                  | 1                   | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Aspiration hazard                                   | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Reproductive toxicity                               | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Effects on or via lactation                         | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Germ cell mutagenicity                              | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Carcinogenicity                                     | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Specific target organ toxicity - single (STOT-SE)   | 3                   | NC     | NC      | NC   | NC              | NC       | NC        | 1    |
| Specific target organ toxicity - repeated (STOT-RE) | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | 1    |

|      |  |
|------|--|
| NC   | Not classified according to CLP criteria               |
| Cat. | Classified according to CLP criteria - Hazard category |

**Table S-8.** Final classification of Environmental hazards (Step 1).

| Environmental hazard         | Raw materials       |        |         |        |                 |          |           |        |
|------------------------------|---------------------|--------|---------|--------|-----------------|----------|-----------|--------|
|                              | Manufacturing stage |        |         |        | Operation stage |          |           |        |
|                              | PMMA                | Rivets | Ethanol | PEEK   | NaOH            | Iron(II) | Iron(III) | TMAH   |
| PBT/vPvB                     | No PBT              | N/A    | No PBT  | No PBT | N/A             | N/A      | N/A       | No PBT |
| PMT/vPvM                     | NC                  | NC     | NC      | NC     | NC              | NC       | NC        | NC     |
| Aquatic toxicity (acute)     | NC                  | NC     | NC      | NC     | NC              | NC       | NC        | NC     |
| Aquatic toxicity (long-term) | NC                  | NC     | NC      | 2      | NC              | NC       | NC        | 2      |
| Ozone layer                  | NC                  | NC     | NC      | NC     | NC              | NC       | NC        | NC     |

|        |  |
|--------|--|
| NC     | Not classified according to CLP criteria               |
| Cat.   | Classified according to CLP criteria - Hazard category |
| No PBT | The substance is not PBT/vPvB                          |
| N/A    | PBT assessment does not apply                          |

**Table S-9.** Final classification of Physical hazards (Step 1).

| Physical hazards                              | Raw materials       |        |         |      |                 |          |           |      |
|---|---------------------|--------|---------|------|-----------------|----------|-----------|------|
|   | Manufacturing stage |        |         |      | Operation stage |          |           |      |
|   | PMMA                | Rivets | Ethanol | PEEK | NaOH            | Iron(II) | Iron(III) | TMAH |
| Explosives                                    | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Flammable gases and chemically unstable gases | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Aerosols                                      | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Oxidising gases                               | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Gases under pressure                          | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Flammable liquids                             | 2                   | NC     | 2       | NC   | NC              | NC       | NC        | NC   |
| Flammable solids                              | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Self-reactive substances                      | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Pyrophoric solids                             | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Self-heating substances                       | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Emits flammable gases                         | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Oxidising liquids                             | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Oxidising solids                              | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Organic peroxides                             | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |
| Corrosive to metals                           | NC                  | NC     | NC      | NC   | 1               | 1        | 1         | NC   |
| Desensitized explosives                       | NC                  | NC     | NC      | NC   | NC              | NC       | NC        | NC   |

|      |  |
|------|--|
| NC   | Not classified according to CLP criteria               |
| Cat. | Classified according to CLP criteria - Hazard category |

**Table S-10.** Scoring of criteria according to the JCR report (Step 1).

| SSbD Level | Conditions   |
|------------|--|
| 3          | If chemicals or materials that pass all safety criteria in Step 1                          |
| 2          | If chemicals or materials that pass hazard criteria H1 and H2 but do not pass criterion H3 |
| 1          | If chemicals or materials that pass hazard criterion H1 but do not pass criterion H2       |
| 0          | If chemicals or materials that do not pass hazard criterion H1                             |

**Table S-11.** Physico-chemical and fate properties information as input for Chesar tool (Step 2).

| Physico-chemical and fate properties                    |  | Raw materials         |                   |                       |                    |                   |                       |                       |                       |
|---|--|-----------------------|-------------------|-----------------------|--------------------|-------------------|-----------------------|-----------------------|-----------------------|
|   |  | Manufacturing stage   |                   |                       |                    | Operation stage   |                       |                       |                       |
|   |  | PMMA                  | Rivets            | Ethanol               | PEEK               | NaOH              | Iron(II)              | Iron(III)             | TMAH                  |
| General   | Physical state at 20°C and 1013 hPa                      | Liquid                | Solid             | Liquid                | Solid              | Solid             | Solid                 | Solid                 | Solid                 |
|   | Molecular weight (for assessment)                        | 100.121               | 63.54             | 46.07                 | 218.20             | 39.997            | 126.75                | 162.21                | 91.15                 |
|   | Melting point at 101 325 Pa (°C)                         | -48                   | 1059              | -114.15               | 108                | 323               | 674                   | 37                    | 63                    |
|   | Vapour pressure (Pa)                                     | 3700 at 20°C          | 0 at 20°C         | 5.73E3 at 20°C        | 0.005 at 20°C      | 10E-5 at 25°C     | 0 at 20°C             | 0 at 20°C             | 0 at 25°C             |
|   | Partition coefficient (Log Kow)                          | 1.38 at 20°C          | No data           | -0.35 at 20°C         | 3.37 at 20°C       | Not applicable    | Not appropriate       | Not appropriate       | 0.036 at 20°C         |
|   | Water solubility   | 15.3 g/L at 20°C      | 1000 mg/L at 20°C | 7.89E5 mg/L at 20°C   | 8.757 mg/L at 20°C | 1110 g/L at 20°C  | 650 g/L at 20°C       | 919 g/L at 20°C       | 1E9 g/L at 20°C       |
|   | Henry's law constant (in Pa m3/mol)                      | 14.7                  | No data           | 0.33                  | 0.12 at 20°C       | No data           | Not relevant          | Not relevant          | 4.4E-11 at 25°C       |
| Biodegradation  | Biodegradation in water: screening tests                 | Readily biodegradable | Not biodegradable | Readily biodegradable | Not biodegradable  | Not biodegradable | Rapidly biodegradable | Rapidly biodegradable | Readily biodegradable |
|   | DT50 in freshwater                                       | No data               | No data           | No data               | No data            | No data           | No data               | No data               | No data               |
|   | DT50 in marine water                                     | No data               | No data           | No data               | No data            | No data           | No data               | No data               | No data               |
|   | DT50 in freshwater sediment                              | No data               | No data           | No data               | No data            | No data           | No data               | No data               | No data               |
|   | DT50 in soil   | No data               | No data           | No data               | No data            | No data           | No data               | No data               | No data               |
| Bioaccumulation   | Bioaccumulation: BCF (aquatic species)                   | No data               | No data           | No data               | No data            | No data           | No data               | No data               | No data               |
|   | Bioaccumulation: BMF in fish                             | No data               | No data           | No data               | No data            | No data           | No data               | No data               | No data               |
|   | Bioaccumulation: BCF (terrestrial species)               | No data               | No data           | No data               | No data            | No data           | No data               | No data               | No data               |
| Abiotic degradation                                     | Degradation rate constant with OH radicals               | No data               | No data           | No data               | No data            | No data           | No data               | No data               | No data               |
|   | DT50 for phototransformation in air                      | No data               | No data           | 38 h                  | No data            | No data           | No data               | No data               | No data               |
|   | DT50 for hydrolysis                                      | No data               | No data           | No data               | No data            | No data           | No data               | No data               | No data               |
|   | DT50 for phototransformation in water                    | No data               | No data           | No data               | No data            | No data           | No data               | No data               | No data               |
| Adsorption coefficients                                 | Adsorption/Desorption: Koc                               | 9.14                  | No data           | No data               | 810                | No data           | No data               | No data               | 563                   |
|   | Log Kp (solids-water in soil) in L/Kg                    | No data               | 3.33 at 20°C      | No data               | No data            | No data           | No data               | No data               | No data               |
|   | Log Kp (solids-water in sediment) in L/Kg                | No data               | 4.39 at 20°C      | No data               | No data            | No data           | 4.997 at 12°C         | 4.997 at 12°C         | No data               |
|   | Log Kp (solids-water in suspended matter) in L/Kg        | No data               | 4.48 at 20°C      | No data               | No data            | No data           | 2.34 at 12°C          | 2.34 at 12°C          | No data               |
|   | Log Kp (solids-water in raw sewage sludge) in L/Kg       | No data               | 4.48 at 20°C      | No data               | No data            | No data           | No data               | No data               | No data               |
|   | Log Kp (solids-water in settled sewage sludge) in L/Kg   | No data               | 4.48 at 20°C      | No data               | No data            | No data           | No data               | No data               | No data               |
|   | Log Kp (solids-water in activated sewage sludge) in L/Kg | No data               | 4.48 at 20°C      | No data               | No data            | No data           | No data               | No data               | No data               |
| Log Kp (solids-water in effluent sewage sludge) in L/Kg | No data  | 4.48 at 20°C          | No data           | No data               | No data            | No data           | No data               | No data               |                       |

**Table S-12. Hazard information as input for Chesar tool (Step 2)**

| Hazards            |  | Raw materials                   |   |                                 |                                 |                               |                                    |                                    |                                 |
|--------------------|--|---------------------------------|---|---------------------------------|---------------------------------|-------------------------------|------------------------------------|------------------------------------|---------------------------------|
|                    |  | Manufacturing stage             |   |                                 |                                 | Operation stage               |                                    |                                    |                                 |
|                    |  | PMMA                            | Rivets  | Ethanol                         | PEEK                            | NaOH                          | Iron(II)                           | Iron(III)                          | TMAH                            |
| Physico-chemical   | Flash point                                | 10 °C                           | No data   | 286 °K                          | 152 °C                          | No data                       | No data                            | No data                            | No data                         |
|                    | Autoflammability/Self-ignition temperature | 435 °C                          | No data   | 636 °K                          | 597 °C                          | No data                       | No data                            | No data                            | No data                         |
|                    | Flammability                               | Flammable                       | Non flammable                                     | Flammable                       | Non flammable                   | Non flammable                 | Non flammable                      | Non flammable                      | Not classified                  |
|                    | Explosiveness                              | Non explosive                   | No data   | Non explosive                   | Non explosive                   | No data                       | Non explosive                      | Non explosive                      | Non explosive                   |
|                    | Oxidising properties                       | Non oxidising                   | No data   | Non oxidising                   | Non oxidising                   | No data                       | Non oxidising                      | Non oxidising                      | Non oxidising                   |
| Environment        | PBT assessment                             | The substance is not PBT / vPvB | PBT assessment does not apply                     | The substance is not PBT / vPvB | The substance is not PBT / vPvB | PBT assessment does not apply | PBT assessment does not apply      | PBT assessment does not apply      | The substance is not PBT / vPvB |
|                    | Freshwater                                 | 0.94 mg/L                       | 6.3 µg/L  | 0.96 mg/L                       | 0.002 mg/L                      | No data                       | No hazard identified               | No hazard identified               | 0.5 µg/L                        |
|                    | Sediment (freshwater)                      | 10.2 mg/kg                      | 87 mg/kg  | 3.6 mg/kg                       | 0.182 mg/kg                     | No data                       | No hazard identified               | No hazard identified               | 30 µg/kg                        |
|                    | Marine water                               | 0.094 mg/L                      | 5.2 µg/L  | 0.79 mg/L                       | 0 mg/L                          | No data                       | No hazard identified               | No hazard identified               | 0.05 µg/L                       |
|                    | Sediment (marine water)                    | 1.02 mg/kg                      | 676 mg/kg   | 2.9 mg/kg                       | 0.018 mg/kg                     | No data                       | No hazard identified               | No hazard identified               | 3 µg/kg                         |
|                    | Sewage treatment plant (STP)               | 10 mg/L                         | 230 µg/L  | 580 mg/L                        | No emission to STP expected     | No data                       | No hazard identified               | No hazard identified               | 5 mg/L                          |
|                    | Air  | No hazard identified            | No hazard identified                              | No hazard identified            | No hazard identified            | No data                       | No hazard identified               | No hazard identified               | No hazard identified            |
|                    | Soil                                       | 1.48 mg/kg                      | 65 mg/kg  | 0.63 mg/kg                      | 0.035 mg/kg                     | No data                       | No hazard identified               | No hazard identified               | 5.7 µg/kg                       |
|                    | Predator's prey (freshwater)               | No potential                    | No potential                                      | 0.38 g/kg                       | No potential                    | No potential                  | No potential                       | No potential                       | No potential                    |
|                    | Predator's prey (marine water)             | No potential                    | No potential                                      | 0.38 g/kg                       | No potential                    | No potential                  | No potential                       | No potential                       | No potential                    |
|                    | Top predator's prey (marine water)         | No potential                    | No potential                                      | 0.38 g/kg                       | No potential                    | No potential                  | No potential                       | No potential                       | No potential                    |
|                    | Predator's prey (terrestrial)              | No potential                    | No potential                                      | 0.38 g/kg                       | No potential                    | No potential                  | No potential                       | No potential                       | No potential                    |
| Workers-Inhalation | Systemic effects - long term exposure      | 348.4 mg/m <sup>3</sup>         | No hazard identified                              | 380 mg/m <sup>3</sup>           | No hazard identified            | No hazard identified          | Insufficient hazard data available | Insufficient hazard data available | 0.164 mg/m <sup>3</sup>         |
|                    | Systemic effects - acute exposure          | No hazard identified            | No hazard identified                              | No hazard identified            | No hazard identified            | No hazard identified          | Low hazard                         | Low hazard                         | High hazard                     |
|                    | Local effects - long term exposure         | 208 mg/m <sup>3</sup>           | other toxicological threshold 1 mg/m <sup>3</sup> | No hazard identified            | No hazard identified            | 1 mg/m <sup>3</sup>           | Insufficient hazard data available | Insufficient hazard data available | High hazard                     |

| Hazards              |                                       | Raw materials          |   |                       |                      |                      |                                    |                                    |                          |
|----------------------|---------------------------------------|------------------------|---|-----------------------|----------------------|----------------------|------------------------------------|------------------------------------|--------------------------|
|                      |                                       | Manufacturing stage    |   |                       |                      | Operation stage      |                                    |                                    |                          |
|                      |                                       | PMMA                   | Rivets  | Ethanol               | PEEK                 | NaOH                 | Iron(II)                           | Iron(III)                          | TMAH                     |
|                      | Local effects - acute exposure        | 416 mg/m <sup>3</sup>  | other toxicological threshold 1 mg/m <sup>3</sup> | No hazard identified  | No hazard identified | No hazard identified | Low hazard                         | Low hazard                         | High hazard              |
| Workers-Dermal       | Systemic effects - long term exposure | 13.67 mg/kg bw/day     | 137 mg/kg bw/day                                  | No hazard identified  | No hazard identified | No hazard identified | 2.8 mg/kg bw/day                   | 2.8 mg/kg bw/day                   | 33.33 µg/kg bw/day       |
|                      | Systemic effects - acute exposure     | No hazard identified   | 273 mg/kg bw/day                                  | No hazard identified  | No hazard identified | No hazard identified | No hazard identified               | No hazard identified               | High hazard              |
|                      | Local effects - long term exposure    | 1.5 mg/cm <sup>2</sup> | No hazard identified                              | No hazard identified  | No hazard identified | High hazard          | Low hazard                         | Low hazard                         | 3.75 µg/cm <sup>2</sup>  |
|                      | Local effects - acute exposure        | 1.5 mg/cm <sup>2</sup> | No hazard identified                              | No hazard identified  | No hazard identified | High hazard          | Low hazard                         | Low hazard                         | High hazard              |
| Workers-Eyes         | Local effects                         | No hazard identified   | No hazard identified                              | Medium hazard         | No hazard identified | High hazard          | Medium hazard                      | Medium hazard                      | High hazard              |
| Consumers-Inhalation | Systemic effects - long term exposure | 74.3 mg/m <sup>3</sup> | No hazard identified                              | 114 mg/m <sup>3</sup> | No hazard identified | No hazard identified | Insufficient hazard data available | Insufficient hazard data available | 0.029 mg/m <sup>3</sup>  |
|                      | Systemic effects - acute exposure     | No hazard identified   | No hazard identified                              | No hazard identified  | No hazard identified | No hazard identified | Low hazard                         | Low hazard                         | High hazard              |
|                      | Local effects - long term exposure    | 104 mg/m <sup>3</sup>  | Other toxicological threshold 1 mg/m <sup>3</sup> | No hazard identified  | No hazard identified | 1 mg/m <sup>3</sup>  | Insufficient hazard data available | Insufficient hazard data available | High hazard              |
|                      | Local effects - acute exposure        | 208 mg/m <sup>3</sup>  | Other toxicological threshold 1 mg/m <sup>3</sup> | No hazard identified  | No hazard identified | No hazard identified | Low hazard                         | Low hazard                         | High hazard              |
| Consumers - Dermal   | Systemic effects - long term exposure | 8.2 mg/kg bw/day       | 137 mg/kg bw/day                                  | No hazard identified  | No hazard identified | No hazard identified | 1.4 mg/kg bw/day                   | 1.4 mg/kg bw/day                   | 16.67 µg/kg bw/day       |
|                      | Systemic effects - acute exposure     | No hazard identified   | 273 mg/kg bw/day                                  | No hazard identified  | No hazard identified | No hazard identified | No hazard identified               | No hazard identified               | High hazard              |
|                      | Local effects - long term exposure    | 1.5 mg/cm <sup>2</sup> | No hazard identified                              | No hazard identified  | No hazard identified | High hazard          | Low hazard                         | Low hazard                         | 1.875 µg/cm <sup>2</sup> |
|                      | Local effects - acute exposure        | 1.5 mg/cm <sup>2</sup> | No hazard identified                              | No hazard identified  | No hazard identified | High hazard          | Low hazard                         | Low hazard                         | High hazard              |
| Consumers - Oral     | Systemic effects - long term exposure | 8.2 mg/kg bw/day       | Other toxicological                               | No hazard identified  | No hazard identified | High hazard          | 0.28 mg/kg bw/day                  | 0.28 mg/kg bw/day                  | 8.33 µg/kg bw/day        |

| Hazards             |               | Raw materials        |                              |               |                      |                 |               |               |             |
|---------------------|---------------|----------------------|------------------------------|---------------|----------------------|-----------------|---------------|---------------|-------------|
|                     |               | Manufacturing stage  |                              |               |                      | Operation stage |               |               |             |
|                     |               | PMMA                 | Rivets                       | Ethanol       | PEEK                 | NaOH            | Iron(II)      | Iron(III)     | TMAH        |
|                     |               |                      | threshold 0.041 mg/kg bw/day |               |                      |                 |               |               |             |
| Consumers<br>- Eyes | Local effects | No hazard identified | Low hazard                   | Medium hazard | No hazard identified | High hazard     | Medium hazard | Medium hazard | High hazard |

**Table S-13.** Generic Exposure Scenarios (GES) for the use of solvents on industrial sites reported by European Solvents Industry Group (ESIG).

| Contributing activity (CA) type | CA name and descriptor |   |         |
|---------------------------------|------------------------|---|---------|
| <b>Manufacture</b>              |                        |   |         |
| Environment                     | CS 1                   | Manufacture of the substance  | ERC1    |
| Workers                         | CS 2                   | General exposures (closed systems)                                    | PROC 1  |
|                                 | CS 3                   | General exposures (closed systems) with sample collection             | PROC 2  |
|                                 | CS 4                   | General exposures (closed systems) batch process                      | PROC 3  |
|                                 | CS 5                   | General exposures   | PROC 4  |
|                                 | CS 6                   | Process sampling  | PROC 8b |
|                                 | CS 7                   | Laboratory activities   | PROC 15 |
|                                 | CS 8                   | Bulk transfers, closed systems  | PROC 8b |
|                                 | CS 9                   | Bulk transfers  | PROC 8b |
|                                 | CS 10                  | Equipment cleaning and maintenance                                    | PROC 8a |
|                                 | CS 11                  | Storage   | PROC 1  |
|                                 | CS 12                  | Storage   | PROC 2  |
| <b>Formulation</b>              |                        |   |         |
| Environment                     | CS 1                   | Distribution of substance   | ERC 2   |
| Workers                         | CS 3                   | General exposures (closed systems)                                    | PROC 1  |
|                                 | CS 4                   | General exposures (closed systems) with sample collection             | PROC 2  |
|                                 | CS 5                   | General exposures (closed systems) batch process                      | PROC 3  |
|                                 | CS 6                   | General exposures   | PROC 4  |
|                                 | CS 7                   | Batch process, elevated temperature, use in contained systems         | PROC 3  |
|                                 | CS 8                   | Process sampling  | PROC 9  |
|                                 | CS 9                   | Laboratory activities   | PROC 15 |
|                                 | CS 10                  | Bulk transfers, dedicated facility                                    | PROC 8b |
|                                 | CS 11                  | Mixing operations   | PROC 5  |
|                                 | CS 12                  | Manual, transfer from/pouring from containers, non-dedicated facility | PROC 8a |
|                                 | CS 13                  | Drum/batch transfers, dedicated facility                              | PROC 8b |
|                                 | CS 14                  | Tabletting, compression, extrusion or pelletisation                   | PROC 14 |

|                    |       |   |         |
|--------------------|-------|---|---------|
|                    | CS 15 | Drum and small package filling                            | PROC 9  |
|                    | CS 16 | Equipment cleaning and maintenance                        | PROC 8a |
|                    | CS 17 | Storage   | PROC 1  |
|                    | CS 18 | Storage   | PROC 2  |
| <b>On-site use</b> |       |   |         |
| Environment        | CS 1  | Use in Process Chemicals                                  | ERC 4   |
| Workers            | CS 2  | General exposures (closed systems)                        | PROC 1  |
|                    | CS 3  | General exposures (closed systems) with sample collection | PROC 2  |
|                    | CS 4  | General exposures (closed systems) batch process          | PROC 3  |
|                    | CS 5  | General exposures   | PROC 4  |
|                    | CS 6  | Laboratory activities                                     | PROC 15 |
|                    | CS 7  | Process sampling  | PROC 9  |
|                    | CS 8  | Equipment cleaning and maintenance                        | PROC 8a |
|                    | CS 9  | Storage   | PROC 1  |
|                    | CS 10 | Storage   | PROC 2  |

**Table S-14.** Risk Characterization Ratios (RCRs) for the environment and man via the environment (Step 2).

| Protection target                     | RCR quantification |        |             |                  |            |                  |                  |              |
|---------------------------------------|--------------------|--------|-------------|------------------|------------|------------------|------------------|--------------|
|                                       | PMMA               | Rivets | Ethanol     | PEEK             | NaOH       | Iron(II)         | Iron(III)        | TMAH         |
| <b>ERC 1</b>                          |                    |        |             |                  |            |                  |                  |              |
| Fresh water                           | RCR = 60.07        | -      | RCR = 65.72 | RCR = 679.6      | -          | -                | -                | RCR = 1.21E5 |
| Sediment (freshwater)                 | RCR = 24.99        | -      | RCR = 75.16 | RCR = 631.8      | -          | -                | -                | RCR = 1.21E5 |
| Marine water                          | RCR = 60.07        | -      | RCR = 7.987 | -                | -          | -                | -                | RCR = 1.21E5 |
| Sediment (marine water)               | RCR = 24.99        | -      | RCR = 9.331 | RCR = 638.8      | -          | -                | -                | RCR = 1.21E5 |
| Sewage Treatment Plant                | RCR = 56.47        | -      | RCR = 1.088 | Qualitative risk | -          | -                | -                | RCR = 120.9  |
| Air                                   | -                  | -      | -           | -                | -          | -                | -                | -            |
| Agricultural soil                     | RCR < 0.01         | -      | RCR < 0.01  | RCR < 0.01       | -          | -                | -                | RCR = 1.32E5 |
| Man via environment - Inhalation      | RCR < 0.01         | -      | RCR < 0.01  | -                | RCR < 0.01 | Qualitative risk | Qualitative risk | RCR < 0.01   |
| Man via environment – Oral            | RCR < 0.01         | -      | -           | -                | -          | -                | -                | RCR = 291.7  |
| Man via environment - combined routes | RCR < 0.01         | -      | -           | -                | -          | -                | -                | RCR = 291.7  |
| <b>ERC 2</b>                          |                    |        |             |                  |            |                  |                  |              |
| Fresh water                           | RCR = 3.004        | -      | RCR = 3.286 | RCR = 45.31      | -          | -                | -                | RCR = 6.05E3 |
| Sediment (freshwater)                 | RCR = 1.25         | -      | RCR = 3.758 | RCR = 42.12      | -          | -                | -                | RCR = 6.03E3 |
| Marine water                          | RCR = 3.004        | -      | RCR = 0.399 | -                | -          | -                | -                | RCR = 6.05E3 |
| Sediment (marine water)               | RCR = 1.25         | -      | RCR = 0.467 | RCR = 42.59      | -          | -                | -                | RCR = 6.03E3 |
| Sewage Treatment Plant                | RCR = 2.824        | -      | RCR = 0.054 | Qualitative risk | -          | -                | -                | RCR = 6.05   |
| Air                                   | -                  | -      | -           | -                | -          | -                | -                | -            |
| Agricultural soil                     | RCR < 0.01         | -      | RCR < 0.01  | RCR = 0.756      | -          | -                | -                | RCR = 0.801  |
| Man via environment - Inhalation      | RCR < 0.01         | -      | RCR < 0.01  | -                | RCR < 0.01 | Qualitative risk | Qualitative risk | RCR = 0.066  |
| Man via environment – Oral            | RCR < 0.01         | -      | -           | -                | -          | -                | -                | RCR = 20.11  |
| Man via environment - combined routes | RCR < 0.01         | -      | -           | -                | -          | -                | -                | RCR = 20.18  |
| <b>ERC 4</b>                          |                    |        |             |                  |            |                  |                  |              |
| Fresh water                           | RCR = 3.004        | -      | RCR = 3.286 | RCR = 33.98      | -          | -                | -                | RCR = 6.05E3 |
| Sediment (freshwater)                 | RCR = 1.25         | -      | RCR = 3.758 | RCR = 31.59      | -          | -                | -                | RCR = 6.05E3 |
| Marine water                          | RCR = 3.004        | -      | RCR = 0.399 | -                | -          | -                | -                | RCR = 6.05E3 |
| Sediment (marine water)               | RCR = 1.25         | -      | RCR = 0.467 | RCR = 31.94      | -          | -                | -                | RCR = 6.05E3 |
| Sewage Treatment Plant                | RCR = 2.824        | -      | RCR = 0.054 | Qualitative risk | -          | -                | -                | RCR = 6.05   |
| Air                                   | -                  | -      | -           | -                | -          | -                | -                | -            |
| Agricultural soil                     | RCR < 0.01         | -      | RCR < 0.01  | RCR < 0.01       | -          | -                | -                | RCR = 0.02   |
| Man via environment - Inhalation      | RCR < 0.01         | -      | RCR < 0.01  | -                | RCR < 0.01 | Qualitative risk | Qualitative risk | RCR < 0.01   |
| Man via environment – Oral            | RCR < 0.01         | -      | -           | -                | -          | -                | -                | RCR = 0.694  |
| Man via environment - combined routes | RCR < 0.01         | -      | -           | -                | -          | -                | -                | RCR = 0.694  |

**Table S-15.** Risk Characterization Ratios (RCRs) in human health for processes in all life cycle (Step 2).

| Process | Manufacture   | Formulation   | On-site use  | Route of exposure and type of effects                 | RCR quantification |            |             |   |                  |                  |                  |                  |                  |
|---------|---------------|---------------|--------------|---|--------------------|------------|-------------|---|------------------|------------------|------------------|------------------|------------------|
|         |               |               |              |   | PMMA               | Rivets     | Ethanol     | PEEK  | NaOH             | Iron(II)         | Iron(III)        | TMAH             |                  |
| PROC 1  | CS 2<br>CS 11 | CS 3<br>CS 17 | CS 2<br>CS 9 | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR < 0.01         | -          | RCR < 0.01  | Exposure assessment and risk characterisation are not required for workers as no hazard has been identified for human health. | RCR = 0.01       | Qualitative risk | Qualitative risk | RCR = 0.061      |                  |
|         |               |               |              | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -                  | -          | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|         |               |               |              | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR < 0.01         | RCR = 0.01 | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|         |               |               |              | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR < 0.01         | RCR = 0.04 | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|         |               |               |              | Dermal, systemic, long term (mg/kg bw/day)            | RCR < 0.01         | RCR < 0.01 | -           |   | -                | -                | RCR = 0.012      | RCR = 0.012      | RCR = 1.02       |
|         |               |               |              | Dermal, systemic, short term (mg/kg bw/day)           | -                  | -          | -           |   | -                | -                | -                | -                | -                |
|         |               |               |              | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR < 0.01         | -          | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 2.644      |
|         |               |               |              | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR < 0.01         | -          | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|         |               |               |              | Combined routes, systemic, long-term                  | RCR < 0.01         | -          | -           |   | -                | -                | -                | -                | RCR = 1.081      |
| PROC 2  | CS 3<br>CS 12 | CS 4<br>CS 18 | CS 3         | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.06         | -          | RCR = 0.025 | RCR = 1   | Qualitative risk | Qualitative risk | RCR = 6.098      |                  |                  |
|         |               |               |              | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -                  | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |                  |
|         |               |               |              | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.1          | RCR = 1    | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |                  |
|         |               |               |              | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.201        | RCR = 4    | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |                  |
|         |               |               |              | Dermal, systemic, long term (mg/kg bw/day)            | RCR < 0.01         | RCR < 0.01 | -           | -   | -                | RCR = 0.024      | RCR = 0.024      | RCR = 2.055      |                  |
|         |               |               |              | Dermal, systemic, short term (mg/kg bw/day)           | -                  | -          | -           | -   | -                | -                | -                | -                |                  |
|         |               |               |              | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR < 0.01         | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 2.664      |                  |
|         |               |               |              | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR < 0.01         | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|         |               |               |              | Combined routes, systemic, long-term                  | RCR = 0.065        | -          | -           | -   | -                | -                | -                | RCR = 8.153      |                  |
| PROC 2  | -             | -             | CS 10        | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.012        | -          | RCR < 0.01  | RCR = 0.2   | Qualitative risk | Qualitative risk | RCR = 1.22       |                  |                  |
|         |               |               |              | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -                  | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |                  |
|         |               |               |              | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.02         | RCR = 0.2  | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |                  |
|         |               |               |              | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.201        | RCR = 4    | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |                  |
|         |               |               |              | Dermal, systemic, long term (mg/kg bw/day)            | RCR < 0.01         | RCR < 0.01 | -           | -   | -                | RCR = 0.024      | RCR = 0.024      | RCR = 2.055      |                  |
|         |               |               |              | Dermal, systemic, short term (mg/kg bw/day)           | -                  | -          | -           | -   | -                | -                | -                | -                |                  |
|         |               |               |              | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR < 0.01         | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 2.664      |                  |
|         |               |               |              | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR < 0.01         | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|         |               |               |              | Combined routes, systemic, long-term                  | RCR = 0.013        | -          | -           | -   | -                | -                | -                | RCR = 3.275      |                  |
| PROC 3  | CS 4          | CS 5          | CS 4         | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.12         | -          | RCR = 0.051 | RCR = 1   | Qualitative risk | Qualitative risk | RCR = 6.098      |                  |                  |
|         |               |               |              | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -                  | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |                  |
|         |               |               |              | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.201        | RCR = 1    | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |                  |
|         |               |               |              | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.401        | RCR = 4    | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |                  |
|         |               |               |              | Dermal, systemic, long term (mg/kg bw/day)            | RCR < 0.01         | RCR < 0.01 | -           | -   | -                | RCR = 0.012      | RCR = 0.012      | RCR = 1.035      |                  |
|         |               |               |              | Dermal, systemic, short term (mg/kg bw/day)           | -                  | -          | -           | -   | -                | -                | -                | -                |                  |
|         |               |               |              | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR < 0.01         | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 2.683      |                  |
|         |               |               |              | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR < 0.01         | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |                  |

|         |       |                |      |   |             |            |             |                  |                  |                  |                  |             |
|---------|-------|----------------|------|---|-------------|------------|-------------|------------------|------------------|------------------|------------------|-------------|
|         |       |                |      | Combined routes, systemic, long-term                  | RCR = 0.122 | -          | -           |                  | -                | -                | -                | RCR = 7.133 |
| PROC 3  | -     | CS 7           | -    | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.06  | -          | RCR = 0.025 |                  | RCR = 0.1        | Qualitative risk | Qualitative risk | RCR = 0.61  |
|         |       |                |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -           | -          | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.1   | RCR = 0.1  | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.201 | RCR = 0.4  | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR < 0.01  | RCR < 0.01 | -           | -                | RCR = 0.012      | RCR = 0.012      | RCR = 1.035      |             |
|         |       |                |      | Dermal, systemic, short term (mg/kg bw/day)           | -           | -          | -           | -                | -                | -                | -                |             |
|         |       |                |      | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR < 0.01  | -          | -           | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 2.683      |             |
|         |       |                |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR < 0.01  | -          | -           | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Combined routes, systemic, long-term                  | RCR = 0.062 | -          | -           | -                | -                | -                | RCR = 1.645      |             |
| PROC 4  | CS 5  | -              | CS 5 | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.168 | -          | RCR = 0.071 |                  | RCR = 17.5       | Qualitative risk | Qualitative risk | RCR = 106.7 |
|         |       |                |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -           | -          | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.281 | RCR = 17.5 | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.562 | RCR = 70   | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR = 0.025 | RCR < 0.01 | -           | -                | RCR = 0.123      | RCR = 0.123      | RCR = 10.29      |             |
|         |       |                |      | Dermal, systemic, short term (mg/kg bw/day)           | -           | -          | -           | -                | -                | -                | -                |             |
|         |       |                |      | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR = 0.033 | -          | -           | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 13.33      |             |
|         |       |                |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR = 0.033 | -          | -           | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Combined routes, systemic, long-term                  | RCR = 0.193 | -          | -           | -                | -                | -                | RCR = 116.9      |             |
| PROC 4  | -     | CS 6           | -    | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.024 | -          | RCR = 0.01  |                  | RCR = 2.5        | Qualitative risk | Qualitative risk | RCR = 15.24 |
|         |       |                |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -           | -          | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.04  | RCR = 2.5  | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.08  | RCR = 10   | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR = 0.025 | RCR < 0.01 | -           | -                | RCR = 0.123      | RCR = 0.123      | RCR = 10.29      |             |
|         |       |                |      | Dermal, systemic, short term (mg/kg bw/day)           | -           | -          | -           | -                | -                | -                | -                |             |
|         |       |                |      | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR = 0.033 | -          | -           | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 13.33      |             |
|         |       |                |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR = 0.033 | -          | -           | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Combined routes, systemic, long-term                  | RCR = 0.049 | -          | -           | -                | -                | -                | RCR = 25.53      |             |
| PROC 5  | -     | CS 11          | -    | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.06  | -          | RCR = 0.025 |                  | RCR = 2.5        | Qualitative risk | Qualitative risk | RCR = 15.24 |
|         |       |                |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -           | -          | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.1   | RCR = 2.5  | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.201 | RCR = 10   | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR = 0.05  | RCR < 0.01 | -           | -                | RCR = 0.245      | RCR = 0.245      | RCR = 20.56      |             |
|         |       |                |      | Dermal, systemic, short term (mg/kg bw/day)           | -           | -          | -           | -                | -                | -                | -                |             |
|         |       |                |      | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR = 0.067 | -          | -           | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 26.65      |             |
|         |       |                |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR = 0.067 | -          | -           | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Combined routes, systemic, long-term                  | RCR = 0.11  | -          | -           | -                | -                | -                | RCR = 35.81      |             |
| PROC 8a | CS 10 | CS 12<br>CS 16 | -    | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.06  | -          | RCR = 0.025 |                  | RCR = 5          | Qualitative risk | Qualitative risk | RCR = 30.48 |
|         |       |                |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -           | -          | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |
|         |       |                |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.1   | RCR = 5    | -           | -                | Qualitative risk | Qualitative risk | Qualitative risk |             |

Exposure assessment and risk characterisation are not required for workers as no hazard has been identified for human health.

|  |                      |                |      |   |                  |                  |             |   |                  |                  |                  |                  |
|--|----------------------|----------------|------|---|------------------|------------------|-------------|---|------------------|------------------|------------------|------------------|
|  |                      |                |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.201      | RCR = 20         | -           | Exposure assessment and risk characterisation are not required for workers as no hazard has been identified for human health. | -                | Qualitative risk | Qualitative risk | Qualitative risk |
|  |                      |                |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR = 0.05       | RCR < 0.01       | -           |   | -                | RCR = 0.245      | RCR = 0.245      | RCR = 20.56      |
|  |                      |                |      | Dermal, systemic, short term (mg/kg bw/day)           | -                | -                | -           |   | -                | -                | -                | -                |
|  |                      |                |      | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR = 0.033      | -                | -           |   | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 13.32      |
|  |                      |                |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR = 0.033      | -                | -           |   | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|  |                      |                |      | Combined routes, systemic, long-term                  | RCR = 0.11       | -                | -           |   | -                | -                | -                | RCR = 51.05      |
| PROC 8a  | -                    | -              | CS 8 | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.042      | -                | RCR = 0.025 |   | RCR = 3.5        | Qualitative risk | Qualitative risk | RCR = 21.34      |
|  |                      |                |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -                | -                | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk |
|  |                      |                |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.07       | RCR = 3.5        | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk |
|  |                      |                |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.14       | RCR = 14         | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk |
|  |                      |                |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR = 0.05       | RCR < 0.01       | -           |   | -                | RCR = 0.245      | RCR = 0.245      | RCR = 20.56      |
|  |                      |                |      | Dermal, systemic, short term (mg/kg bw/day)           | -                | -                | -           |   | -                | -                | -                | -                |
|  |                      |                |      | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR = 0.033      | -                | -           |   | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 13.32      |
|  |                      |                |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR = 0.033      | -                | -           |   | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
| PROC 8b  | CS 6<br>CS 8<br>CS 9 | CS 10<br>CS 13 | -    | Combined routes, systemic, long-term                  | RCR = 0.092      | -                | -           |   | -                | -                | -                | RCR = 41.90      |
|  |                      |                |      | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.299      | -                | RCR = 0.126 |   | RCR = 25         | Qualitative risk | Qualitative risk | RCR = 152.4      |
|  |                      |                |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -                | -                | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk |
|  |                      |                |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.501      | RCR = 25         | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk |
|  |                      |                |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 1.003      | RCR = 100        | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk |
|  |                      |                |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR = 0.05       | RCR < 0.01       | -           |   | -                | RCR = 0.245      | RCR = 0.245      | RCR = 20.56      |
|  |                      |                |      | Dermal, systemic, short term (mg/kg bw/day)           | -                | -                | -           |   | -                | -                | -                | -                |
|  |                      |                |      | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR = 0.033      | -                | -           |   | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 13.32      |
| PROC 9   | -                    | CS 8           | -    | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR = 0.033      | -                | -           |   | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|  |                      |                |      | Combined routes, systemic, long-term                  | RCR = 0.349      | -                | -           |   | -                | -                | -                | RCR = 173.0      |
|  |                      |                |      | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.599      | -                | RCR = 0.253 | RCR = 20  | Qualitative risk | Qualitative risk | RCR = 30.48      |                  |
|  |                      |                |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -                | -                | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|  |                      |                |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 1.003      | RCR = 20         | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|  |                      |                |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 2.006      | RCR = 80         | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|  |                      |                |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR = 0.025      | RCR < 0.01       | -           | -   | RCR = 0.123      | RCR = 0.123      | RCR = 10.29      |                  |
|  |                      |                |      | Dermal, systemic, short term (mg/kg bw/day)           | -                | -                | -           | -   | -                | -                | -                |                  |
| PROC 9   | -                    | CS 15          | -    | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR = 0.033      | -                | -           | Qualitative risk  | Qualitative risk | Qualitative risk | RCR = 13.33      |                  |
|  |                      |                |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR = 0.033      | -                | -           | Qualitative risk  | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|  |                      |                |      | Combined routes, systemic, long-term                  | RCR = 0.624      | -                | -           | -   | -                | -                | RCR = 132.2      |                  |
|  |                      |                |      | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.06       | -                | RCR = 0.025 | RCR = 2   | Qualitative risk | Qualitative risk | RCR = 12.19      |                  |
|  |                      |                |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -                | -                | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|  |                      |                |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.1        | RCR = 2          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|  |                      |                |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.201      | RCR = 8          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk |                  |
| Dermal, systemic, long term (mg/kg bw/day)           | RCR = 0.025          | RCR < 0.01     | -    | -   | RCR = 0.123      | RCR = 0.123      | RCR = 10.29 |   |                  |                  |                  |                  |
| Dermal, systemic, short term (mg/kg bw/day)          | -                    | -              | -    | -   | -                | -                | -           |   |                  |                  |                  |                  |
| Dermal, local, long term (mg/cm <sup>2</sup> bw/day) | RCR = 0.033          | -              | -    | Qualitative risk                                      | Qualitative risk | Qualitative risk | RCR = 13.33 |   |                  |                  |                  |                  |

|         |      |       |      |   |             |            |             |   |                  |                  |                  |                  |                  |
|---------|------|-------|------|---|-------------|------------|-------------|---|------------------|------------------|------------------|------------------|------------------|
|         |      |       |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR = 0.033 | -          | -           | Exposure assessment and risk characterisation are not required for workers as no hazard has been identified for human health. | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|         |      |       |      | Combined routes, systemic, long-term                  | RCR = 0.085 | -          | -           |   | -                | -                | -                | -                | RCR = 22.48      |
| PROC 9  | -    | -     | CS 7 | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.599 | -          | RCR = 0.253 |   | RCR = 20         | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 121.9      |
|         |      |       |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -           | -          | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|         |      |       |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 1.003 | RCR = 20   | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|         |      |       |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 2.006 | RCR = 80   | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|         |      |       |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR = 0.025 | RCR < 0.01 | -           |   | -                | -                | RCR = 0.123      | RCR = 0.123      | RCR = 10.29      |
|         |      |       |      | Dermal, systemic, short term (mg/kg bw/day)           | -           | -          | -           |   | -                | -                | -                | -                | -                |
|         |      |       |      | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR = 0.033 | -          | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 13.33      |
|         |      |       |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR = 0.033 | -          | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|         |      |       |      | Combined routes, systemic, long-term                  | RCR = 0.624 | -          | -           |   | -                | -                | -                | -                | RCR = 132.2      |
| PROC 14 | -    | CS 14 | -    | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.06  | -          | RCR = 0.025 |   | RCR = 1          | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 6.098      |
|         |      |       |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -           | -          | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|         |      |       |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.1   | RCR = 1    | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|         |      |       |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.201 | RCR = 4    | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|         |      |       |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR = 0.013 | RCR < 0.01 | -           |   | -                | -                | RCR = 0.061      | RCR = 0.061      | RCR = 5.146      |
|         |      |       |      | Dermal, systemic, short term (mg/kg bw/day)           | -           | -          | -           |   | -                | -                | -                | -                | -                |
|         |      |       |      | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR = 0.017 | -          | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 6.669      |
|         |      |       |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR = 0.017 | -          | -           |   | -                | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |
|         |      |       |      | Combined routes, systemic, long-term                  | RCR = 0.072 | -          | -           |   | -                | -                | -                | -                | RCR = 11.24      |
| PROC 15 | CS 7 | CS 9  | CS 6 | Inhalation, systemic, long term (mg/m <sup>3</sup> )  | RCR = 0.12  | -          | RCR = 0.051 | RCR = 5   | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 30.48      |                  |
|         |      |       |      | Inhalation, systemic, short term (mg/m <sup>3</sup> ) | -           | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|         |      |       |      | Inhalation, local, long term (mg/m <sup>3</sup> )     | RCR = 0.201 | RCR = 5    | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|         |      |       |      | Inhalation, local, short term (mg/m <sup>3</sup> )    | RCR = 0.401 | RCR = 20   | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|         |      |       |      | Dermal, systemic, long term (mg/kg bw/day)            | RCR < 0.01  | RCR < 0.01 | -           | -   | -                | RCR < 0.01       | RCR < 0.01       | RCR = 0.51       |                  |
|         |      |       |      | Dermal, systemic, short term (mg/kg bw/day)           | -           | -          | -           | -   | -                | -                | -                | -                |                  |
|         |      |       |      | Dermal, local, long term (mg/cm <sup>2</sup> bw/day)  | RCR < 0.01  | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | RCR = 1.332      |                  |
|         |      |       |      | Dermal, local, short term (mg/cm <sup>2</sup> bw/day) | RCR < 0.01  | -          | -           | -   | Qualitative risk | Qualitative risk | Qualitative risk | Qualitative risk |                  |
|         |      |       |      | Combined routes, systemic, long-term                  | RCR = 0.121 | -          | -           | -   | -                | -                | -                | RCR = 30.99      |                  |

**Table S-16.** Scoring of RCR quantification (Step 2)

| SSbD Level | Conditions   |
|------------|--|
| 3          | If total RCR<=1                                    |
| 2          | If total RCR>1 but all individual RCRs<1           |
| 1          | If total RCR>1 but at least 1 individual RCRs>1    |
| 0          | If total RCR>1 and more than one individual RCRs>1 |

**Table S-17.** Scoring of processes involved in the manufacturing stage of each raw material according to the criteria defined in SSbD (Step 2)

|                     | Process            | Manufacturing |        |         |      |      |          |           |      |
|---------------------|--------------------|---------------|--------|---------|------|------|----------|-----------|------|
|                     |                    | PMMA          | Rivets | Ethanol | PEEK | NaOH | Iron(II) | Iron(III) | TMAH |
| <b>Environment</b>  | ERC 1              | 0             | 3      | 0       | 0    | 3    | 3        | 3         | 0    |
| <b>Human health</b> | PROC 1             | 3             | 3      | 3       | 3    | 3    | 3        | 3         | 0    |
|                     | PROC 2             | 3             | 3      | 3       | 3    | 3    | 3        | 3         | 0    |
|                     | PROC 3             | 3             | 3      | 3       | 3    | 3    | 3        | 3         | 0    |
|                     | PROC 4             | 3             | 3      | 3       | 3    | 1    | 3        | 3         | 0    |
|                     | PROC 8a            | 3             | 3      | 3       | 3    | 1    | 3        | 3         | 0    |
|                     | PROC 8b            | 3             | 3      | 3       | 3    | 1    | 3        | 3         | 0    |
|                     | PROC 15            | 3             | 3      | 3       | 3    | 1    | 3        | 3         | 0    |
|                     | Total human health | 21            | 21     | 21      | 21   | 13   | 21       | 21        | 0    |

| SSbD Level | Total score | Safety          |
|------------|-------------|-----------------|
| 3          | 16-21       | Negligible risk |
| 2          | 10-15       | Medium risk     |
| 1          | 5-9         | High risk       |
| 0          | 0-4         | Very high risk  |

**Table S-18.** Scoring of processes involved in the formulation stage of each raw material according to the criteria defined in SSbD (Step 2).

|                     | Process            | Formulation |        |         |      |      |          |           |      |   |
|---------------------|--------------------|-------------|--------|---------|------|------|----------|-----------|------|---|
|                     |                    | PMMA        | Rivets | Ethanol | PEEK | NaOH | Iron(II) | Iron(III) | TMAH |   |
| <b>Environment</b>  | ERC 2              | 0           | 3      | 0       | 0    | 3    | 3        | 3         | 0    |   |
| <b>Human health</b> | PROC 1             | 3           | 3      | 3       | 3    | 3    | 3        | 3         | 0    |   |
|                     | PROC 2             | 3           | 3      | 3       | 3    | 3    | 3        | 3         | 0    |   |
|                     | PROC 3             | 3           | 3      | 3       | 3    | 3    | 3        | 3         | 0    |   |
|                     | PROC 3             | 3           | 3      | 3       | 3    | 3    | 3        | 3         | 0    |   |
|                     | PROC 4             | 3           | 3      | 3       | 3    | 1    | 3        | 3         | 0    |   |
|                     | PROC 5             | 3           | 3      | 3       | 3    | 1    | 3        | 3         | 0    |   |
|                     | PROC 8a            | 3           | 3      | 3       | 3    | 1    | 3        | 3         | 0    |   |
|                     | PROC 8b            | 3           | 3      | 3       | 3    | 1    | 3        | 3         | 0    |   |
|                     | PROC 9             | 3           | 3      | 3       | 3    | 1    | 3        | 3         | 0    |   |
|                     | PROC 9             | 3           | 3      | 3       | 3    | 1    | 3        | 3         | 0    |   |
|                     | PROC 14            | 3           | 3      | 3       | 3    | 3    | 3        | 3         | 0    |   |
|                     | PROC 15            | 3           | 3      | 3       | 3    | 1    | 3        | 3         | 0    |   |
|                     | Total human health |             | 36     | 36      | 36   | 36   | 22       | 36        | 36   | 0 |

| SSbD Level | Total score | Safety          |
|------------|-------------|-----------------|
| 3          | 27-36       | Negligible risk |
| 2          | 18-26       | Medium risk     |
| 1          | 9-17        | High risk       |
| 0          | 0-8         | Very high risk  |

**Table S-19.** Scoring of processes involved in the use stage of each raw material according to the criteria defined in SSbD (Step 2).

|                     | Process | On-site use |        |         |      |      |          |           |      |
|---------------------|---------|-------------|--------|---------|------|------|----------|-----------|------|
|                     |         | PMMA        | Rivets | Ethanol | PEEK | NaOH | Iron(II) | Iron(III) | TMAH |
| <b>Environment</b>  | ERC 4   | 0           | 3      | 0       | 0    | 3    | 3        | 3         | 0    |
| <b>Human health</b> | PROC 1  | 3           | 3      | 3       | 3    | 3    | 3        | 3         | 0    |
|                     | PROC 2  | 3           | 3      | 3       | 3    | 3    | 3        | 3         | 0    |
|                     | PROC 2  | 3           | 3      | 3       | 3    | 3    | 3        | 3         | 0    |

|  |                    |    |    |    |    |    |    |    |   |
|--|--------------------|----|----|----|----|----|----|----|---|
|  | PROC 3             | 3  | 3  | 3  | 3  | 3  | 3  | 3  | 0 |
|  | PROC 4             | 3  | 3  | 3  | 3  | 1  | 3  | 3  | 0 |
|  | PROC 8a            | 3  | 3  | 3  | 3  | 1  | 3  | 3  | 0 |
|  | PROC 9             | 3  | 3  | 3  | 3  | 1  | 3  | 3  | 0 |
|  | PROC 15            | 3  | 3  | 3  | 3  | 1  | 3  | 3  | 0 |
|  | Total human health | 24 | 24 | 24 | 24 | 16 | 24 | 24 | 0 |


| SSbD Level | Total score | Safety          |
|------------|-------------|-----------------|
| 3          | 18-24       | Negligible risk |
| 2          | 12-17       | Medium risk     |
| 1          | 6-11        | High risk       |
| 0          | 0-5         | Very high risk  |

**Table S-20.** Summary of scores for each raw material during the manufacturing, formulation, and on-site use stages (Step 2).


|           | Manufacturing |              | Formulation |              | On-site use |              |
|-----------|---------------|--------------|-------------|--------------|-------------|--------------|
|           | Environment   | Human health | Environment | Human health | Environment | Human health |
| PMMA      | 0             | 3            | 0           | 3            | 0           | 3            |
| Rivets    | 3             | 3            | 3           | 3            | 3           | 3            |
| Ethanol   | 0             | 3            | 0           | 3            | 0           | 3            |
| PEEK      | 0             | 3            | 0           | 3            | 0           | 3            |
| NaOH      | 3             | 2            | 3           | 2            | 3           | 2            |
| Iron(II)  | 3             | 3            | 3           | 3            | 3           | 3            |
| Iron(III) | 3             | 3            | 3           | 3            | 3           | 3            |
| TMAH      | 0             | 0            | 0           | 0            | 0           | 0            |

| SSbD Level | Safety          |
|------------|-----------------|
| 3          | Negligible risk |
| 2          | Medium risk     |
| 1          | High risk       |
| 0          | Very high risk  |



**Figure S-2.** Tissue-specific accumulation of MNPs@Laccase in Zebrafish at different exposure concentrations. Data adapted from Guillén-Pacheco et al. study.<sup>2</sup>



**Figure S-3.** Impact categories of the ReCiPe 2016 midpoint (H) method aligned with the SSbD framework (Step 4).

**Table S-21.** Scores to be applied for each impact category (Step 4).

| SSbD score | Conditions                   |
|------------|------------------------------|
| 3          | Improvement $\geq$ 20%       |
| 2          | Improvement $\geq$ 5% to 20% |
| 1          | Improvement > 0% to 5%       |
| 0          | No improvement               |

**Table S-22.** Impact assessment results of the reference process with rivets fittings in the manufacturing stage. Adapted from Fuentes et al.<sup>3</sup> (Step 4).

|   | Electricity | Ethanol   | PMMA      | Rivets    | PEEK Tubing | Deionized water | Lorry     | Ship      |
|---|-------------|-----------|-----------|-----------|-------------|-----------------|-----------|-----------|
| <b>Reference</b>                        |             |           |           |           |             |                 |           |           |
| Fine particulate matter formation       | 1,129E+00   | 7,183E-01 | 2,477E+00 | 3,833E+01 | 7,370E-01   | 7,440E-04       | 2,324E-01 | 1,274E+00 |
| Fossil resource scarcity                | 2,528E+02   | 6,115E+01 | 6,596E+02 | 1,024E+03 | 2,446E+02   | 8,114E-02       | 5,716E+01 | 7,388E+01 |
| Freshwater ecotoxicity                  | 3,006E+01   | 5,743E+00 | 8,108E+00 | 4,895E+03 | 1,108E+01   | 9,383E-03       | 2,327E+00 | 1,570E+00 |
| Freshwater eutrophication               | 3,145E-01   | 7,723E-02 | 8,004E-02 | 2,727E+01 | 1,472E-01   | 1,573E-04       | 1,317E-02 | 3,133E-02 |
| Global warming                          | 8,136E+02   | 2,596E+02 | 2,070E+03 | 3,473E+03 | 5,162E+02   | 3,206E-01       | 1,620E+02 | 2,331E+02 |
| Human carcinogenic toxicity             | 2,574E+01   | 8,133E+00 | 4,200E+01 | 1,205E+03 | 1,517E+01   | 3,707E-02       | 3,427E+00 | 4,825E+00 |
| Human non-carcinogenic toxicity         | 5,179E+02   | 2,232E+02 | 1,949E+02 | 1,851E+05 | 2,992E+02   | 2,381E-01       | 9,585E+01 | 4,061E+01 |
| Ionizing radiation                      | 3,037E+00   | 8,527E+00 | 8,399E-01 | 7,355E+02 | 1,934E+01   | 2,529E-02       | 3,050E+00 | 9,346E+00 |
| Land use                                | 3,078E+00   | 6,508E+01 | 7,056E-01 | 8,374E+01 | 1,872E+00   | 1,598E-03       | 6,751E+00 | 5,510E-01 |
| Marine ecotoxicity                      | 3,923E+01   | 7,388E+00 | 1,108E+01 | 7,148E+03 | 1,396E+01   | 1,308E-02       | 4,318E+00 | 2,436E+00 |
| Marine eutrophication                   | 1,997E-02   | 3,073E-01 | 1,145E-01 | 1,675E+00 | 9,568E-03   | 1,254E-05       | 1,102E-03 | 2,293E-03 |
| Mineral resource scarcity               | 7,687E-01   | 8,548E-01 | 2,591E-01 | 4,398E+02 | 9,019E-01   | 1,380E-03       | 2,966E-01 | 2,835E-01 |
| Ozone formation, Human health           | 1,726E+00   | 8,570E-01 | 4,096E+00 | 2,001E+01 | 1,108E+00   | 7,638E-04       | 8,582E-01 | 3,011E+00 |
| Ozone formation, Terrestrial ecosystems | 1,738E+00   | 8,787E-01 | 4,483E+00 | 2,046E+01 | 1,226E+00   | 7,737E-04       | 8,750E-01 | 3,034E+00 |
| Stratospheric ozone depletion           | 4,481E-04   | 2,130E-03 | 1,711E-05 | 5,876E-03 | 9,341E-05   | 2,528E-07       | 7,112E-05 | 1,096E-04 |
| Terrestrial acidification               | 3,203E+00   | 2,331E+00 | 7,936E+00 | 1,111E+02 | 1,459E+00   | 1,191E-03       | 5,317E-01 | 3,887E+00 |
| Terrestrial ecotoxicity                 | 7,397E+02   | 8,458E+02 | 3,539E+02 | 7,414E+05 | 9,546E+02   | 6,553E-01       | 2,338E+03 | 4,384E+02 |
| Water consumption                       | 1,591E+00   | 4,747E+01 | 7,655E+00 | 5,294E+01 | 5,929E+00   | 2,116E-01       | 4,787E-01 | 6,902E-01 |

**Table S-23.** Impact assessment results of the alternative process with PEEK fittings in the manufacturing stage. Adapted from Fuentes et al.<sup>3</sup> (Step 4).

|             | Impact categories                       | Electricity | Ethanol   | PMMA      | PEEK fittings | PEEK Tubing | Deionized water | Lorry     | Ship      |
|-------------|---|-------------|-----------|-----------|---------------|-------------|-----------------|-----------|-----------|
| Alternative | Fine particulate matter formation       | 1,129E+00   | 7,183E-01 | 2,477E+00 | 1,73E-02      | 7,370E-01   | 7,440E-04       | 2,324E-01 | 1,274E+00 |
|             | Fossil resource scarcity                | 2,528E+02   | 6,115E+01 | 6,596E+02 | 5,75E+00      | 2,446E+02   | 8,114E-02       | 5,716E+01 | 7,388E+01 |
|             | Freshwater ecotoxicity                  | 3,006E+01   | 5,743E+00 | 8,108E+00 | 2,60E-01      | 1,108E+01   | 9,383E-03       | 2,327E+00 | 1,570E+00 |
|             | Freshwater eutrophication               | 3,145E-01   | 7,723E-02 | 8,004E-02 | 3,46E-03      | 1,472E-01   | 1,573E-04       | 1,317E-02 | 3,133E-02 |
|             | Global warming                          | 8,136E+02   | 2,596E+02 | 2,070E+03 | 1,21E+01      | 5,162E+02   | 3,206E-01       | 1,620E+02 | 2,331E+02 |
|             | Human carcinogenic toxicity             | 2,574E+01   | 8,133E+00 | 4,200E+01 | 3,57E-01      | 1,517E+01   | 3,707E-02       | 3,427E+00 | 4,825E+00 |
|             | Human non-carcinogenic toxicity         | 5,179E+02   | 2,232E+02 | 1,949E+02 | 7,04E+00      | 2,992E+02   | 2,381E-01       | 9,585E+01 | 4,061E+01 |
|             | Ionizing radiation                      | 3,037E+00   | 8,527E+00 | 8,399E-01 | 4,55E-01      | 1,934E+01   | 2,529E-02       | 3,050E+00 | 9,346E+00 |
|             | Land use                                | 3,078E+00   | 6,508E+01 | 7,056E-01 | 4,40E-02      | 1,872E+00   | 1,598E-03       | 6,751E+00 | 5,510E-01 |
|             | Marine ecotoxicity                      | 3,923E+01   | 7,388E+00 | 1,108E+01 | 3,28E-01      | 1,396E+01   | 1,308E-02       | 4,318E+00 | 2,436E+00 |
|             | Marine eutrophication                   | 1,997E-02   | 3,073E-01 | 1,145E-01 | 2,25E-04      | 9,568E-03   | 1,254E-05       | 1,102E-03 | 2,293E-03 |
|             | Mineral resource scarcity               | 7,687E-01   | 8,548E-01 | 2,591E-01 | 2,12E-02      | 9,019E-01   | 1,380E-03       | 2,966E-01 | 2,835E-01 |
|             | Ozone formation, Human health           | 1,726E+00   | 8,570E-01 | 4,096E+00 | 2,61E-02      | 1,108E+00   | 7,638E-04       | 8,582E-01 | 3,011E+00 |
|             | Ozone formation, Terrestrial ecosystems | 1,738E+00   | 8,787E-01 | 4,483E+00 | 2,88E-02      | 1,226E+00   | 7,737E-04       | 8,750E-01 | 3,034E+00 |
|             | Stratospheric ozone depletion           | 4,481E-04   | 2,130E-03 | 1,711E-05 | 2,20E-06      | 9,341E-05   | 2,528E-07       | 7,112E-05 | 1,096E-04 |
|             | Terrestrial acidification               | 3,203E+00   | 2,331E+00 | 7,936E+00 | 3,43E-02      | 1,459E+00   | 1,191E-03       | 5,317E-01 | 3,887E+00 |
|             | Terrestrial ecotoxicity                 | 7,397E+02   | 8,458E+02 | 3,539E+02 | 2,24E+01      | 9,546E+02   | 6,553E-01       | 2,338E+03 | 4,384E+02 |
|             | Water consumption                       | 1,591E+00   | 4,747E+01 | 7,655E+00 | 1,39E-01      | 5,929E+00   | 2,116E-01       | 4,787E-01 | 6,902E-01 |

**Table S-24.** Impact assessment results of the reference process with TMAH in the operation stage. Adapted from Fuentes et al.<sup>3</sup> (Step 4).

|                  | Impact categories                       | Electricity | Iron (II) | Iron (III) | NaOH     | TMAH     | Deionized water | Lorry    | Ship     |
|------------------|---|-------------|-----------|------------|----------|----------|-----------------|----------|----------|
| <b>Reference</b> | Fine particulate matter formation       | 2,00E+01    | 5,64E+01  | 2,63E+02   | 4,39E+02 | 1,82E+01 | 6,18E+01        | 9,11E+01 | 4,84E+02 |
|                  | Fossil resource scarcity                | 4,48E+03    | 5,69E+03  | 2,87E+04   | 4,81E+04 | 4,02E+03 | 6,74E+03        | 2,24E+04 | 2,80E+04 |
|                  | Freshwater ecotoxicity                  | 5,33E+02    | 1,73E+03  | 9,58E+03   | 6,71E+03 | 1,86E+02 | 7,79E+02        | 9,12E+02 | 5,96E+02 |
|                  | Freshwater eutrophication               | 5,57E+00    | 1,72E+01  | 1,00E+02   | 1,10E+02 | 2,33E+00 | 1,31E+01        | 5,16E+00 | 1,19E+01 |
|                  | Global warming                          | 1,44E+04    | 2,22E+04  | 1,10E+05   | 1,91E+05 | 1,04E+04 | 2,66E+04        | 6,35E+04 | 8,85E+04 |
|                  | Human carcinogenic toxicity             | 4,56E+02    | 1,68E+03  | 9,30E+03   | 9,21E+03 | 3,17E+02 | 3,08E+03        | 1,34E+03 | 1,83E+03 |
|                  | Human non-carcinogenic toxicity         | 9,18E+03    | 5,66E+04  | 3,11E+05   | 1,92E+05 | 5,78E+03 | 1,98E+04        | 3,76E+04 | 1,54E+04 |
|                  | Ionizing radiation                      | 5,38E+01    | 2,58E+03  | 2,32E+04   | 2,22E+04 | 3,80E+02 | 2,10E+03        | 1,20E+03 | 3,55E+03 |
|                  | Land use                                | 5,46E+01    | 1,82E+02  | 9,40E+02   | 1,17E+03 | 4,47E+01 | 1,33E+02        | 2,65E+03 | 2,09E+02 |
|                  | Marine ecotoxicity                      | 6,95E+02    | 2,48E+03  | 1,37E+04   | 9,42E+03 | 2,67E+02 | 1,09E+03        | 1,69E+03 | 9,25E+02 |
|                  | Marine eutrophication                   | 3,54E-01    | 1,07E+00  | 7,37E+00   | 1,06E+01 | 2,17E+00 | 1,04E+00        | 4,32E-01 | 8,71E-01 |
|                  | Mineral resource scarcity               | 1,36E+01    | 2,10E+02  | 1,15E+03   | 5,50E+02 | 1,85E+01 | 1,15E+02        | 1,16E+02 | 1,08E+02 |
|                  | Ozone formation, Human health           | 3,06E+01    | 6,74E+01  | 3,37E+02   | 4,82E+02 | 3,06E+01 | 6,34E+01        | 3,36E+02 | 1,14E+03 |
|                  | Ozone formation, Terrestrial ecosystems | 3,08E+01    | 6,83E+01  | 3,41E+02   | 4,87E+02 | 3,13E+01 | 6,42E+01        | 3,43E+02 | 1,15E+03 |
|                  | Stratospheric ozone depletion           | 7,94E-03    | 1,02E-02  | 9,15E-02   | 2,05E-01 | 1,95E-02 | 2,10E-02        | 2,79E-02 | 4,16E-02 |
|                  | Terrestrial acidification               | 5,68E+01    | 1,06E+02  | 5,62E+02   | 7,38E+02 | 4,33E+01 | 9,89E+01        | 2,08E+02 | 1,48E+03 |
|                  | Terrestrial ecotoxicity                 | 1,31E+04    | 1,84E+05  | 1,00E+06   | 5,66E+05 | 1,91E+04 | 5,44E+04        | 9,17E+05 | 1,66E+05 |
|                  | Water consumption                       | 2,82E+01    | 1,63E+02  | 2,10E+03   | 4,83E+03 | 8,22E+01 | 1,76E+04        | 1,88E+02 | 2,62E+02 |

**Table S-25.** Impact assessment results of the reference process with sodium metasilicate in the operation stage (Step 4).

|                    | Impact categories                       | Electricity | Iron (II) | Iron (III) | NaOH     | Sodium metasilicate | Deionized water | Lorry    | Ship     |
|--------------------|---|-------------|-----------|------------|----------|---------------------|-----------------|----------|----------|
| <b>Alternative</b> | Fine particulate matter formation       | 2,00E+01    | 5,64E+01  | 2,63E+02   | 4,39E+02 | 2,04E+01            | 6,18E+01        | 9,11E+01 | 4,84E+02 |
|                    | Fossil resource scarcity                | 4,48E+03    | 5,69E+03  | 2,87E+04   | 4,81E+04 | 9,40E+02            | 6,74E+03        | 2,24E+04 | 2,80E+04 |
|                    | Freshwater ecotoxicity                  | 5,33E+02    | 1,73E+03  | 9,58E+03   | 6,71E+03 | 1,54E+02            | 7,79E+02        | 9,12E+02 | 5,96E+02 |
|                    | Freshwater eutrophication               | 5,57E+00    | 1,72E+01  | 1,00E+02   | 1,10E+02 | 1,84E+00            | 1,31E+01        | 5,16E+00 | 1,19E+01 |
|                    | Global warming                          | 1,44E+04    | 2,22E+04  | 1,10E+05   | 1,91E+05 | 3,49E+03            | 2,66E+04        | 6,35E+04 | 8,85E+04 |
|                    | Human carcinogenic toxicity             | 4,56E+02    | 1,68E+03  | 9,30E+03   | 9,21E+03 | 1,73E+02            | 3,08E+03        | 1,34E+03 | 1,83E+03 |
|                    | Human non-carcinogenic toxicity         | 9,18E+03    | 5,66E+04  | 3,11E+05   | 1,92E+05 | 4,77E+03            | 1,98E+04        | 3,76E+04 | 1,54E+04 |
|                    | Ionizing radiation                      | 5,38E+01    | 2,58E+03  | 2,32E+04   | 2,22E+04 | 3,08E+02            | 2,10E+03        | 1,20E+03 | 3,55E+03 |
|                    | Land use                                | 5,46E+01    | 1,82E+02  | 9,40E+02   | 1,17E+03 | 2,73E+01            | 1,33E+02        | 2,65E+03 | 2,09E+02 |
|                    | Marine ecotoxicity                      | 6,95E+02    | 2,48E+03  | 1,37E+04   | 9,42E+03 | 2,20E+02            | 1,09E+03        | 1,69E+03 | 9,25E+02 |
|                    | Marine eutrophication                   | 3,54E-01    | 1,07E+00  | 7,37E+00   | 1,06E+01 | 1,54E-01            | 1,04E+00        | 4,32E-01 | 8,71E-01 |
|                    | Mineral resource scarcity               | 1,36E+01    | 2,10E+02  | 1,15E+03   | 5,50E+02 | 1,59E+01            | 1,15E+02        | 1,16E+02 | 1,08E+02 |
|                    | Ozone formation, Human health           | 3,06E+01    | 6,74E+01  | 3,37E+02   | 4,82E+02 | 9,20E+00            | 6,34E+01        | 3,36E+02 | 1,14E+03 |
|                    | Ozone formation, Terrestrial ecosystems | 3,08E+01    | 6,83E+01  | 3,41E+02   | 4,87E+02 | 9,33E+00            | 6,42E+01        | 3,43E+02 | 1,15E+03 |
|                    | Stratospheric ozone depletion           | 7,94E-03    | 1,02E-02  | 9,15E-02   | 2,05E-01 | 2,75E-03            | 2,10E-02        | 2,79E-02 | 4,16E-02 |
|                    | Terrestrial acidification               | 5,68E+01    | 1,06E+02  | 5,62E+02   | 7,38E+02 | 1,35E+01            | 9,89E+01        | 2,08E+02 | 1,48E+03 |
|                    | Terrestrial ecotoxicity                 | 1,31E+04    | 1,84E+05  | 1,00E+06   | 5,66E+05 | 1,77E+04            | 5,44E+04        | 9,17E+05 | 1,66E+05 |
|                    | Water consumption                       | 2,82E+01    | 1,63E+02  | 2,10E+03   | 4,83E+03 | 6,15E+01            | 1,76E+04        | 1,88E+02 | 2,62E+02 |

**Table S-26.** List of considered stakeholder categories, impact subcategories and indicators. Adapted from Caldeira et al. (2022).

| Stakeholder categories | Impact subcategories                             | PSILCA indicators  | Reference unit      |
|------------------------|--|--|---------------------|
| <b>Workers</b>         | Child labor                                      | Child Labour   Female  | CL med risk hours   |
|                        |  | Child Labour   Male  | CL med risk hours   |
|                        |  | Child Labour   Total   | CL med risk hours   |
|                        | Discrimination                                   | Discrimination   Gender wage gap   | GW med risk hours   |
|                        |  | Discrimination   Men in the sectoral labour force                                    | M med risk hours    |
|                        |  | Discrimination   Women in the sectoral labour force                                  | W med risk hours    |
|                        | Fair Salary                                      | Fair Salary  | FS med risk hours   |
|                        | Forced Labour                                    | Forced Labour   Frequency of forced labour   | FL med risk hours   |
|                        |  | Forced Labour   Goods produced by forced labour                                      | GFL med risk hours  |
|                        |  | Forced Labour   Trafficking in persons   | TP med risk hours   |
|                        | Freedom of Association and Collective Bargaining | Freedom of Association and Collective Bargaining   Association and bargaining rights | ACB med risk hours  |
|                        |  | Freedom of Association and Collective Bargaining   Trade unionism                    | TU med risk hours   |
|                        | Health and Safety                                | Health and Safety   DALYs due to indoor and outdoor air and water pollution          | DALY med risk hours |
|                        |  | Health and Safety   Fatal accidents  | FA med risk hours   |
|                        |  | Health and Safety   Non-fatal accidents  | NFA med risk hours  |
|                        |  | Health and Safety   Safety measures  | SM med risk hours   |
|                        |  | Health and Safety   Workers affected by natural disasters                            | ND med risk hours   |
|                        | Social benefits, legal issues                    | Social benefits, legal issues   Social security expenditures                         | SS med risk hours   |
|                        |  | Social benefits, legal issues   Violations of employment laws and regulations        | VL med risk hours   |
|                        | Working Time                                     | Working Time   Weekly hours of work per employee                                     | WH med risk hours   |

**Table S-27.** Social inventory of MNPs production (100 ton/year).

| Process activity | Amount        | Unit | PSILCA dataset                                      |
|------------------|---------------|------|---|
| Materials        | 21.950.966,40 | USD  | Manufacture of chemicals and chemical products - CO |
| Electricity      | 9.680,70      | USD  | Electric power - CO                                 |
| Water            | 14.830,10     | USD  | Water - CO  |
| Transport        | 116.036,0     | USD  | Land transport - CO                                 |



**Figure S-4.** Social impact risks related to workers (expressed in medium risk work hours).

## REFERENCES

- (1) Peñaranda, P. A.; Noguera, M. J.; Florez, S. L.; Husserl, J.; Ornelas-Soto, N.; Cruz, J. C.; Osma, J. F. Treatment of Wastewater, Phenols and Dyes Using Novel Magnetic Torus Microreactors and Laccase Immobilized on Magnetite Nanoparticles. *Nanomaterials* **2022**, *12* (10). <https://doi.org/10.3390/nano12101688>.
- (2) Guillén, A.; Ardila, Y.; Noguera, M. J.; Campaña, A. L.; Bejarano, M.; Akle, V.; Osma, J. F. Toxicity of Modified Magnetite-Based Nanocomposites Used for Wastewater Treatment and Evaluated on Zebrafish (Danio Rerio) Model. *Nanomaterials* **2022**, *12* (3). <https://doi.org/10.3390/nano12030489>.
- (3) Fuentes, O. P.; Cruz, J. C.; Mignard, E.; Sonnemann, G.; Osma, J. F. Life Cycle Assessment of Magnetite Production Using Microfluidic Devices: Moving from the Laboratory to Industrial Scale. *ACS Sustain Chem Eng* **2023**, *11* (18), 6932–6943. <https://doi.org/10.1021/acssuschemeng.2c06875>.